Betaine regulates the gut-liver axis: a therapeutic approach for chronic liver diseases

被引:0
|
作者
Perumal, Sathish Kumar [1 ,2 ]
Arumugam, Madan Kumar [1 ,2 ,3 ]
Osna, Natalia A. [4 ]
Rasineni, Karuna [5 ]
Kharbanda, Kusum K. [1 ,2 ,5 ]
机构
[1] Nebraska Western Iowa Hlth Care Syst, Dept Vet Affairs, Res Serv, Omaha, NE 68803 USA
[2] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE 68198 USA
[3] Sathyabama Inst Sci & Technol, Ctr Mol & Nanomed Sci, Canc Biol Lab, Chennai, Tamil Nadu, India
[4] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE USA
[5] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA
来源
FRONTIERS IN NUTRITION | 2025年 / 12卷
关键词
betaine; liver; alcohol-associated liver disease; metabolic dysfunction-associated steatotic liver disease; gut-liver axis; intestinal barrier integrity; gut microbiome; NONALCOHOLIC FATTY LIVER; INCREASED INTESTINAL PERMEABILITY; HOMOCYSTEINE METHYLTRANSFERASE BHMT; ELEVATED S-ADENOSYLHOMOCYSTEINE; ALCOHOL-INDUCED ENDOTOXEMIA; CHRONIC ETHANOL-CONSUMPTION; HEPATIC LIPID-ACCUMULATION; CACO-2 CELL MONOLAYERS; RECEPTOR; EXPRESSION; TIGHT JUNCTIONS;
D O I
10.3389/fnut.2025.1478542
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Chronic liver disease is defined by persistent harm to the liver that might result in decreased liver function. The two prevalent chronic liver diseases are alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD). There is ample evidence that the pathogenesis of these two chronic liver diseases is closely linked to gastrointestinal dysfunctions that alters the gut-liver crosstalk. These alterations are mediated through the imbalances in the gut microbiota composition/function that combined with disruption in the gut barrier integrity allows for harmful gut microbes and their toxins to enter the portal circulation and reach the liver to elicit an inflammatory response. This leads to further recruitment of systemic inflammatory cells, such as neutrophils, T-cells, and monocytes into the liver, which perpetuate additional inflammation and the development of progressive liver damage. Many therapeutic modalities, currently used to prevent, attenuate, or treat chronic liver diseases are aimed at modulating gut dysbiosis and improving intestinal barrier function. Betaine is a choline-derived metabolite and a methyl group donor with antioxidant, anti-inflammatory and osmoprotectant properties. Studies have shown that low betaine levels are associated with higher levels of organ damage. There have been several publications demonstrating the role of betaine supplementation in preventing the development of ALD and MASLD. This review explores the protective effects of betaine through its role as a methyl donor and its capacity to regulate the protective gut microbiota and maintain intestinal barrier integrity to prevent the development of these chronic liver diseases. Further studies are needed to enhance our understanding of its therapeutic potential that could pave the way for targeted interventions in the management of not only chronic liver diseases, but other inflammatory bowel diseases or systemic inflammatory conditions.
引用
收藏
页数:19
相关论文
共 50 条
  • [1] Gut-liver axis: Pathophysiological concepts and medical perspective in chronic liver diseases
    Rodrigues, Susana G.
    van der Merwe, Schalk
    Krag, Aleksander
    Wiest, Reiner
    SEMINARS IN IMMUNOLOGY, 2024, 71
  • [2] The Gut-Liver Axis in Cholestatic Liver Diseases
    Blesl, Andreas
    Stadlbauer, Vanessa
    NUTRIENTS, 2021, 13 (03) : 1 - 32
  • [3] The gut-liver axis in hepatobiliary diseases
    Masataka Ichikawa
    Haruka Okada
    Nobuhiro Nakamoto
    Nobuhito Taniki
    Po-Sung Chu
    Takanori Kanai
    Inflammation and Regeneration, 44
  • [4] The gut-liver axis in hepatobiliary diseases
    Ichikawa, Masataka
    Okada, Haruka
    Nakamoto, Nobuhiro
    Taniki, Nobuhito
    Chu, Po-Sung
    Kanai, Takanori
    INFLAMMATION AND REGENERATION, 2024, 44 (01)
  • [5] The Gut-liver Axis in Immune Remodeling: New insight into Liver Diseases
    Yang, Xinyu
    Lu, Di
    Zhuo, Jianyong
    Lin, Zuyuan
    Yang, Modan
    Xu, Xiao
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2020, 16 (13): : 2357 - 2366
  • [6] Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases
    Bruneau, Alix
    Hundertmark, Jana
    Guillot, Adrien
    Tacke, Frank
    FRONTIERS IN MEDICINE, 2021, 8
  • [7] Microbiome interplays in the gut-liver axis: implications for liver cancer pathogenesis and therapeutic insights
    Wang, Xuran
    Zhang, Bin
    Jiang, Runqiu
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2025, 15
  • [8] The gut-liver axis
    Visschers, Ruben G. J.
    Luyer, Misha D.
    Schaap, Frank G.
    Damink, Steven W. M. Olde
    Soeters, Peter B.
    CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2013, 16 (05) : 576 - 581
  • [9] The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective
    De Muynck, Kevin
    Vanderborght, Bart
    Van Vlierberghe, Hans
    Devisscher, Lindsey
    CELLS, 2021, 10 (11)
  • [10] Importance of the gut microbiota in the gut-liver axis in normal and liver disease
    Kotlyarov, Stanislav
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (06)